Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Google Secures Pentagon AI Deal for Classified Projects 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
ST. LOUIS, April 27, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Monday, May 8, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2017 financial results conference call |
| When: | Monday, May 8th at 10:00 a.m. Eastern Time (7:00 a.m. PT) |
| Dial In Number: | To access the live call, dial 877-675-4756 (US and Canada) or 719-325-4839 (International) and give the participant pass code 3960816. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com |
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 15, 2017. To access the replay dial-in information, please click here. |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts: David L. Fischel Chairman and Acting Chief Executive Officer Martin C. Stammer Chief Financial Officer [email protected]
